ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: Community ASSN. Developing Clinical Standards Catalogue; Perry Leaves NCI For NIH Position

November 15, 1974

NCAB TO Reconsider Decision Not To Fund Diet Fit Trial

October 20, 1989

Drug Bills Cut $500 Million From Cancer Care, ASCO Says.

July 4, 2003

Breast Cancer Rates Decline Most for Affluent White Women

February 26, 2010

High Dose Chemotherapy Significantly Prolongs Survival In ECOG Clinical Trial

November 28, 2008

No Site Visit For Georgetown Lombardi as Federal Government Shuts Down

October 4, 2013